Upgrade to SI Premium - Free Trial

Select Medical Holdings Corporation Announces Results For Its First Quarter Ended March 31, 2020

April 30, 2020 4:30 PM

MECHANICSBURG, Pa., April 30, 2020 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its first quarter ended March 31, 2020.

For the first quarter ended March 31, 2020, net operating revenues increased 6.8% to $1,414.6 million, compared to $1,324.6 million for the same quarter, prior year. Income from operations increased 15.2% to $128.7 million for the first quarter ended March 31, 2020, compared to $111.7 million for the same quarter, prior year. Net income increased 32.1% to $70.4 million for the first quarter ended March 31, 2020, compared to $53.3 million for the same quarter, prior year. For both the first quarters ended March 31, 2020 and 2019, net income included pre-tax gains on sales of businesses of $7.2 million and $6.5 million, respectively. Adjusted EBITDA increased 10.1% to $187.3 million for the first quarter ended March 31, 2020, compared to $170.1 million for the same quarter, prior year. Earnings per common share increased to $0.40 on a fully diluted basis for the first quarter ended March 31, 2020, compared to $0.30 for the same quarter, prior year. Adjusted earnings per common share was $0.37 on a fully diluted basis for the first quarter ended March 31, 2020, compared to $0.27 for the same quarter, prior year. Adjusted earnings per common share excludes the gains on sales of businesses and their related tax effects for both of the quarters ended March 31, 2020 and 2019. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table VI of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table VII of this release.

Please refer to "Effects of the COVID-19 Pandemic on Select Medical's Results of Operations" for further discussion regarding the impact of the coronavirus disease 2019 ("COVID-19") pandemic on Select Medical's operating results for the first quarter ended March 31, 2020.

Company Overview

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities. Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of March 31, 2020, Select Medical operated 101 critical illness recovery hospitals in 28 states, 29 rehabilitation hospitals in 12 states, and 1,753 outpatient rehabilitation clinics in 37 states and the District of Columbia. Select Medical's joint venture subsidiary Concentra operated 523 occupational health centers in 41 states. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics. At March 31, 2020, Select Medical had operations in 47 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

Critical Illness Recovery Hospital Segment

For the first quarter ended March 31, 2020, net operating revenues for the critical illness recovery hospital segment increased 9.4% to $500.5 million, compared to $457.5 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 21.3% to $88.6 million for the first quarter ended March 31, 2020, compared to $73.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 17.7% for the first quarter ended March 31, 2020, compared to 16.0% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table V of this release for both the first quarters ended March 31, 2020 and 2019.

Rehabilitation Hospital Segment

For the first quarter ended March 31, 2020, net operating revenues for the rehabilitation hospital segment increased 17.8% to $182.0 million, compared to $154.6 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 49.5% to $38.6 million for the first quarter ended March 31, 2020, compared to $25.8 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 21.2% for the first quarter ended March 31, 2020, compared to 16.7% for the same quarter, prior year. For the first quarter ended March 31, 2019, the Adjusted EBITDA results for the rehabilitation hospital segment include start-up losses of approximately $2.8 million. Certain rehabilitation hospital key statistics are presented in table V of this release for both the first quarters ended March 31, 2020 and 2019.

Outpatient Rehabilitation Segment

For the first quarter ended March 31, 2020, net operating revenues for the outpatient rehabilitation segment increased 3.4% to $255.2 million, compared to $246.9 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment was $27.1 million for the first quarter ended March 31, 2020, compared to $29.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 10.6% for the first quarter ended March 31, 2020, compared to 11.7% for the same quarter, prior year. Certain outpatient rehabilitation key statistics are presented in table V of this release for both the first quarters ended March 31, 2020 and 2019.

Concentra Segment

For the first quarter ended March 31, 2020, net operating revenues for the Concentra segment increased 0.6% to $398.5 million, compared to $396.3 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment was $61.5 million for the first quarter ended March 31, 2020, compared to $66.3 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 15.4% for the first quarter ended March 31, 2020, compared to 16.7% for the same quarter, prior year. Certain Concentra key statistics are presented in table V of this release for both the first quarters ended March 31, 2020 and 2019.

Effects of the COVID-19 Pandemic on Select Medical's Results of Operations

The broader implications of the COVID-19 pandemic on Select Medical's results of operations and overall financial performance remain uncertain. Select Medical is a healthcare service provider that provides patient care services in both inpatient and outpatient settings. Select Medical has provided certain additional performance metrics to assist readers in understanding how the COVID-19 pandemic impacted each of its segments during the one month ended March 31, 2020, including its (i) net operating revenues and Adjusted EBITDA for the two months ended February 29, 2020 and February 28, 2019, (ii) net operating revenues and Adjusted EBITDA for the one month ended March 31, 2020 and 2019, (iii) net operating revenues and Adjusted EBITDA for the quarters ended March 31, 2020 and 2019, and (iv) certain operating statistics for each of the aforementioned periods.

Critical Illness Recovery Hospital Segment. Select Medical's critical illness recovery hospitals are a key part of the inpatient hospital continuum of care. Both the Centers for Medicare & Medicaid Services ("CMS") and Congress acted to temporarily suspend certain regulations concerning length of stay requirements, which impact Select Medical's critical illness recovery hospitals, in order to facilitate the transfer of patients from general acute care hospitals. This was done in order to expand hospital bed capacity to care for COVID-19 patients. As COVID-19 has spread in the general acute care hospitals in many markets where it operates, Select Medical has admitted patients with COVID-19 and has faced the challenging task of treating them while attempting to protect its patients and staff members who do not have COVID-19. The hospitals have followed CDC guidelines, directives and recommendations with regard to the use of personal protective equipment and the isolation and treatment of patients with COVID-19. The pandemic has caused, and will continue to cause, disruptions in Select Medical's critical illness recovery hospitals, which include, in some cases, the addition or reduction of beds, the creation of isolated units and spaces, temporary increases or restrictions on admissions, the incurrence of additional costs, staff illnesses, and the increased use of contract clinical labor.

Rehabilitation Hospital Segment. Select Medical's rehabilitation hospitals receive most of their admissions from general acute care hospitals. Both CMS and Congress acted to temporarily suspend certain regulations that govern admissions into rehabilitation hospitals to facilitate the transfer of patients from general acute care hospitals and critical illness recovery hospitals. This was done in order to expand hospital bed capacity to care for COVID-19 patients. As COVID-19 has spread in the general acute care hospitals in many markets where it operates, Select Medical has admitted patients with COVID-19 and has faced the challenging task of treating them while attempting to protect its patients and staff members who do not have COVID-19. The hospitals have followed CDC guidelines, directives and recommendations with regard to the use of personal protective equipment and the isolation and treatment of patients with COVID-19. The pandemic has caused, and will continue to cause, disruptions in Select Medical's rehabilitation hospitals, which include, in some cases, the addition or reduction of beds, the creation of isolated units and spaces, temporary restrictions on admissions, the incurrence of additional costs, staff illnesses, and the increased use of contract clinical labor. Additionally, elective surgeries at hospitals and other facilities have been suspended which is reducing the need for inpatient rehabilitation services.

Outpatient Rehabilitation Segment. Beginning in mid-March, hospitals and other facilities began to suspend elective surgeries. Additionally, state governments in the areas experiencing the most significant growth of COVID-19 infections began implementing mandatory closures of non-essential or non-life sustaining businesses, restrictions on individual activities outside of the home, restrictions on travel, and closures of schools. These actions continued to expand throughout March and by the end of March, most states implemented significant restrictions on businesses and individuals. The suspension of elective surgeries at hospitals and other facilities and the reduction of physician office visits combined with recommendations of social distancing and the other items noted above have had significant effects on patient visit volumes. As a result, Select Medical has temporarily consolidated the operations of some of its clinics by transferring staff and patients.

Concentra Segment. Beginning in mid-March, state governments in the areas experiencing the most significant growth of COVID-19 infections began implementing mandatory closures of non-essential or non-life sustaining businesses. These actions have continued to expand throughout March. By the end of March, most states implemented significant restrictions on businesses. These actions have had significant effects on patient visit volumes as employers have furloughed workforces and temporarily ceased operations or have significantly reduced their operations. As a result, Select Medical has temporarily consolidated the operations of some of its centers by transferring staff and patients.

Select Medical provided below certain performance measures and operating statistics used by management to help illustrate the impact of the COVID-19 pandemic on its operating results. For the quarter ended March 31, 2020, Select Medical defined the pre-COVID-19 outbreak period as the two months ended February 29, 2020, and the post-COVID-19 outbreak period as the one month ended March 31, 2020. Select Medical provided prior year comparative data for the pre-COVID-19 and post-COVID-19 outbreak periods presented. The following performance measures and operating statistics should be considered in conjunction with the operating results for the full quarter ended March 31, 2020. The performance measures and operating statistics presented for the two months ended February 29, 2020 and the one month ended March 31, 2020 are, when combined, equal to the performance measures and operating statistics presented for the full quarter ended March 31, 2020. The same is true for the prior year comparative data.

Two Months Ended February

One Month Ended March

Three Months Ended March

2019

2020

%

Change

2019

2020

%

Change

2019

2020

Selected financial data:

Net operating revenues:

Critical illness recovery hospital

$

295,385

$

328,613

11.2

%

$

162,149

$

171,908

6.0

%

$

457,534

$

500,521

Rehabilitation hospital

98,695

122,363

24.0

55,863

59,656

6.8

154,558

182,019

Outpatient rehabilitation

161,758

179,163

10.8

85,147

76,086

(10.6)

246,905

255,249

Concentra

259,816

274,926

5.8

136,505

123,609

(9.4)

396,321

398,535

Other(1)

38,532

54,283

40.9

30,781

24,025

(21.9)

69,313

78,308

Total Company

$

854,186

$

959,348

12.3

%

$

470,445

$

455,284

(3.2)

%

$

1,324,631

$

1,414,632

Income (loss) from operations:

Critical illness recovery hospital

$

36,355

$

48,395

33.1

%

$

25,192

$

27,839

10.5

%

$

61,547

$

76,234

Rehabilitation hospital

11,605

22,855

96.9

7,790

8,827

13.3

19,395

31,682

Outpatient rehabilitation

12,623

18,289

44.9

9,336

1,615

(82.7)

21,959

19,904

Concentra

23,373

29,624

26.7

17,214

8,188

(52.4)

40,587

37,812

Other(1)

(22,432)

(24,868)

(10.9)

(9,332)

(12,086)

(29.5)

(31,764)

(36,954)

Total Company

$

61,524

$

94,295

53.3

%

$

50,200

$

34,383

(31.5)

%

$

111,724

$

128,678

Adjusted EBITDA:

Critical illness recovery hospital

$

44,035

$

56,648

28.6

%

$

28,963

$

31,922

10.2

%

$

72,998

$

88,570

Rehabilitation hospital

15,908

27,448

72.5

9,889

11,121

12.5

25,797

38,569

Outpatient rehabilitation

17,265

23,062

33.6

11,726

4,060

(65.4)

28,991

27,122

Concentra

40,785

45,537

11.7

25,473

15,929

(37.5)

66,258

61,466

Other(1)

(17,278)

(19,281)

(11.6)

(6,649)

(9,113)

(37.1)

(23,927)

(28,394)

Total Company

$

100,715

$

133,414

32.5

%

$

69,402

$

53,919

(22.3)

%

$

170,117

$

187,333

Adjusted EBITDA margins:

Critical illness recovery hospital

14.9

%

17.2

%

17.9

%

18.6

%

16.0

%

17.7

%

Rehabilitation hospital

16.1

22.4

17.7

18.6

16.7

21.2

Outpatient rehabilitation

10.7

12.9

13.8

5.3

11.7

10.6

Concentra

15.7

16.6

18.7

12.9

16.7

15.4

Other(1)

N/M

N/M

N/M

N/M

N/M

N/M

Total Company

11.8

%

13.9

%

14.8

%

11.8

%

12.8

%

13.2

%

Two Months Ended February

One Month Ended March

Three Months Ended March

2019

2020

%

Change

2019

2020

%

Change

2019

2020

Operating statistics:

Critical illness recovery hospital:

Admissions

6,303

6,427

2.0

%

3,153

3,106

(1.5)

%

9,456

9,533

Patient days

167,044

178,627

6.9

%

91,085

91,831

0.8

%

258,129

270,458

Occupancy rate

70

%

70

%

73

%

70

%

71

%

70

%

Rehabilitation hospital:

Admissions

3,758

4,412

17.4

%

2,078

1,921

(7.6)

%

5,836

6,333

Patient days

52,876

63,924

20.9

%

29,940

30,644

2.4

%

82,816

94,568

Occupancy rate

75

%

81

%

78

%

76

%

76

%

79

%

Outpatient rehabilitation:

Number of visits

1,345,617

1,496,232

11.2

%

708,866

626,433

(11.6)

%

2,054,483

2,122,665

Concentra:

Number of visits

1,904,663

1,997,810

4.9

%

1,006,944

879,585

(12.6)

%

2,911,607

2,877,395

(1)

Other includes corporate administration and shared services, as well as employee leasing services with non-consolidating subsidiaries.

N/M

Not meaningful

Stock Repurchase Program

The board of directors of Select Medical has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2020, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.

During the quarter ended March 31, 2020, Select Medical repurchased 491,559 shares at a cost of approximately $8.7 million, an average cost per share of $17.68, which includes transaction costs. Since the inception of the program through March 31, 2020, Select Medical has repurchased 38,580,908 shares at a cost of approximately $356.6 million, or $9.24 per share, which includes transaction costs.

Conference Call

Select Medical will host a conference call regarding its first quarter results, as well as its business outlook and the impact of the COVID-19 pandemic on each of its reportable segments, on Friday, May 1, 2020, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 2296334. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation's website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 12:00pm ET, May 8, 2020. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 2296334. The replay can also be accessed at Select Medical Holdings Corporation's website, www.selectmedicalholdings.com.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

  • developments related to the COVID-19 pandemic including, but not limited to, the duration and severity of the pandemic, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
  • changes in government reimbursement for our services and/or new payment policies may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;
  • the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;
  • the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;
  • a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
  • acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;
  • our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
  • private third-party payors for our services may adopt payment policies that could limit our future net operating revenues and profitability;
  • the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;
  • shortages in qualified nurses, therapists, physicians, or other licensed providers, or the inability to attract or retain healthcare professionals due to the heightened risk of infection related to the COVID-19 pandemic, could increase our operating costs significantly or limit our ability to staff our facilities;
  • competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;
  • the loss of key members of our management team could significantly disrupt our operations;
  • the effect of claims asserted against us could subject us to substantial uninsured liabilities;
  • a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
  • other factors discussed from time to time in our filings with the Securities and Exchange Commission (the "SEC"), including factors discussed under the heading "Risk Factors" of the quarterly reports on Form 10-Q and of the annual report on Form 10-K for the year ended December 31, 2019.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:

Joel T. Veit Senior Vice President and Treasurer 717-972-1100 [email protected]

I. Condensed Consolidated Statements of Operations For the Three Months Ended March 31, 2019 and 2020 (In thousands, except per share amounts, unaudited)

2019

2020

% Change

Net operating revenues

$

1,324,631

$

1,414,632

6.8

%

Costs and expenses:

Cost of services

1,132,092

1,200,371

6.0

General and administrative

28,677

33,831

18.0

Depreciation and amortization

52,138

51,752

(0.7)

Income from operations

111,724

128,678

15.2

Equity in earnings of unconsolidated subsidiaries

4,366

2,588

(40.7)

Gain on sale of businesses

6,532

7,201

N/M

Interest expense

(50,811)

(46,107)

(9.3)

Income before income taxes

71,811

92,360

28.6

Income tax expense

18,467

21,912

18.7

Net income

53,344

70,448

32.1

Less: Net income attributable to non-controlling interests

12,510

17,323

38.5

Net income attributable to Select Medical

$

40,834

$

53,125

30.1

%

Diluted earnings per common share:(1)

$

0.30

$

0.40

(1)

Refer to table II for calculation of earnings per common share.

N/M

Not meaningful

II. Earnings per Share For the Three Months Ended March 31, 2019 and 2020 (In thousands, except per share amounts, unaudited)

Select Medical's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings.

The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three months ended March 31, 2019 and 2020:

Diluted EPS

Three Months EndedMarch 31,

2019

2020

Net income

$

53,344

$

70,448

Less: net income attributable to non-controlling interests

12,510

17,323

Net income attributable to Select Medical

40,834

53,125

Less: net income attributable to participating securities

1,343

1,818

Net income attributable to common shares

$

39,491

$

51,307

The following tables set forth the computation of EPS under the two-class method for the three months ended March 31, 2019 and 2020:

Three Months Ended March 31,

2019

2020

Net Income Allocation

Shares(1)

Diluted EPS

Net Income Allocation

Shares(1)

Diluted EPS

Common shares

$

39,491

130,861

$

0.30

$

51,307

129,638

$

0.40

Participating securities

1,343

4,449

$

0.30

1,818

4,594

$

0.40

Total

$

40,834

$

53,125

(1)

Represents the weighted average share count outstanding during the period.

III. Condensed Consolidated Balance Sheets (In thousands, unaudited)

December 31, 2019

March 31, 2020

Assets

Current Assets:

Cash and cash equivalents

$

335,882

$

73,163

Accounts receivable

762,677

816,405

Other current assets

114,433

108,462

Total Current Assets

1,212,992

998,030

Operating lease right-of-use assets

1,003,986

1,014,969

Property and equipment, net

998,406

978,547

Goodwill

3,391,955

3,391,078

Identifiable intangible assets, net

409,068

405,374

Other assets

323,881

327,569

Total Assets

$

7,340,288

$

7,115,567

Liabilities and Equity

Current Liabilities:

Payables and accruals

$

681,163

$

613,909

Current operating lease liabilities

207,950

212,884

Current portion of long-term debt and notes payable

25,167

17,161

Total Current Liabilities

914,280

843,954

Non-current operating lease liabilities

852,897

860,796

Long-term debt, net of current portion

3,419,943

3,553,056

Non-current deferred tax liability

148,258

158,782

Other non-current liabilities

101,334

103,783

Total Liabilities

5,436,712

5,520,371

Redeemable non-controlling interests

974,541

620,377

Total equity

929,035

974,819

Total Liabilities and Equity

$

7,340,288

$

7,115,567

IV. Condensed Consolidated Statements of Cash Flows For the Three Months Ended March 31, 2019 and 2020 (In thousands, unaudited)

2019

2020

Operating activities

Net income

$

53,344

$

70,448

Adjustments to reconcile net income to net cash provided by operating activities:

Distributions from unconsolidated subsidiaries

7,872

8,479

Depreciation and amortization

52,138

51,752

Provision for bad debts

1,567

199

Equity in earnings of unconsolidated subsidiaries

(4,366)

(2,588)

Gain on sale of assets and businesses

(6,233)

(7,339)

Stock compensation expense

6,255

6,903

Amortization of debt discount, premium and issuance costs

3,231

553

Deferred income taxes

(81)

9,364

Changes in operating assets and liabilities, net of effects of business combinations:

Accounts receivable

(74,752)

(53,928)

Other current assets

(7,523)

27

Other assets

57,319

2,248

Accounts payable and accrued expenses

(64,839)

(53,447)

Income taxes

17,830

11,413

Net cash provided by operating activities

41,762

44,084

Investing activities

Business combinations, net of cash acquired

(6,120)

(6,833)

Purchases of property and equipment

(49,073)

(39,208)

Investment in businesses

(27,608)

(9,848)

Proceeds from sale of assets and businesses

2

11,230

Net cash used in investing activities

(82,799)

(44,659)

Financing activities

Borrowings on revolving facilities

360,000

460,000

Payments on revolving facilities

(220,000)

(295,000)

Payments on term loans

(132,685)

(39,843)

Borrowings of other debt

8,290

6,487

Principal payments on other debt

(6,155)

(8,099)

Repurchase of common stock

(8,691)

Increase in overdrafts

6,050

Proceeds from issuance of non-controlling interests

3,425

1,679

Distributions to and purchases of non-controlling interests

(5,251)

(12,474)

Purchase of membership interests of Concentra Group Holdings Parent

(366,203)

Net cash provided by (used in) financing activities

13,674

(262,144)

Net decrease in cash and cash equivalents

(27,363)

(262,719)

Cash and cash equivalents at beginning of period

175,178

335,882

Cash and cash equivalents at end of period

$

147,815

$

73,163

Supplemental information

Cash paid for interest

$

37,199

$

67,885

Cash paid for taxes

718

1,135

V. Key Statistics For the Three Months Ended March 31, 2019 and 2020 (unaudited)

2019(g)

2020

% Change

Critical Illness Recovery Hospital

Number of hospitals – end of period(a)

97

101

Net operating revenues (,000)

$

457,534

$

500,521

9.4

%

Number of patient days(b)(c)

258,129

270,458

4.8

%

Number of admissions(b)(d)

9,456

9,533

0.8

%

Net revenue per patient day(b)(e)

$

1,759

$

1,839

4.5

%

Adjusted EBITDA (,000)

$

72,998

$

88,570

21.3

%

Adjusted EBITDA margin

16.0

%

17.7

%

Rehabilitation Hospital

Number of hospitals – end of period(a)

27

29

Net operating revenues (,000)

$

154,558

$

182,019

17.8

%

Number of patient days(b)(c)

82,816

94,568

14.2

%

Number of admissions(b)(d)

5,836

6,333

8.5

%

Net revenue per patient day(b)(e)

$

1,633

$

1,732

6.1

%

Adjusted EBITDA (,000)

$

25,797

$

38,569

49.5

%

Adjusted EBITDA margin

16.7

%

21.2

%

Outpatient Rehabilitation

Number of clinics – end of period(a)

1,684

1,753

Net operating revenues (,000)

$

246,905

$

255,249

3.4

%

Number of visits(b)

2,054,483

2,122,665

3.3

%

Revenue per visit(b)(f)

$

103

$

104

1.0

%

Adjusted EBITDA (,000)

$

28,991

$

27,122

(6.4)

%

Adjusted EBITDA margin

11.7

%

10.6

%

Concentra

Number of centers – end of period(b)

525

523

Net operating revenues (,000)

$

396,321

$

398,535

0.6

%

Number of visits(b)

2,911,607

2,877,395

(1.2)

%

Revenue per visit(b)(f)

$

124

$

123

(0.8)

%

Adjusted EBITDA (,000)

$

66,258

$

61,466

(7.2)

%

Adjusted EBITDA margin

16.7

%

15.4

%

(a)

Includes managed locations.

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

(d)

Represents the number of patients admitted to our hospitals during the periods presented.

(e)

Represents the average amount of revenue recognized for each patient day. Net revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

(f)

Represents the average amount of revenue recognized for each patient visit. Net revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits.

(g)

For the three months ended March 31, 2019, the financial results of Select Medical's reportable segments have been changed to remove the net operating revenues and expenses associated with employee leasing services provided to its non-consolidating subsidiaries. These results are now reported as part of Select Medical's other activities. Select Medical leases employees at cost to these non-consolidating subsidiaries.

VI. Net Income to Adjusted EBITDA Reconciliation For the Three Months Ended March 31, 2019 and 2020 (In thousands, unaudited)

The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used to evaluate financial performance and determine resource allocation for each of Select Medical's operating segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles ("GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.

Three Months EndedMarch 31,

2019

2020

Net income

$

53,344

$

70,448

Income tax expense

18,467

21,912

Interest expense

50,811

46,107

Gain on sale of businesses

(6,532)

(7,201)

Equity in earnings of unconsolidated subsidiaries

(4,366)

(2,588)

Income from operations

111,724

128,678

Stock compensation expense:

Included in general and administrative

4,748

5,437

Included in cost of services

1,507

1,466

Depreciation and amortization

52,138

51,752

Adjusted EBITDA

$

170,117

$

187,333

Critical illness recovery hospital

$

72,998

$

88,570

Rehabilitation hospital

25,797

38,569

Outpatient rehabilitation

28,991

27,122

Concentra

66,258

61,466

Other(a)

(23,927)

(28,394)

Adjusted EBITDA

$

170,117

$

187,333

(a)

Other primarily includes general and administrative costs.

VII. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share For the Three Months Ended March 31, 2019 and 2020 (In thousands, except per share amounts, unaudited)

Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Select Medical's ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.

The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.

Three Months Ended March 31,

2019

Per Share(a)

2020

Per Share(a)

Net income attributable to common shares(a)

$

39,491

$

0.30

$

51,307

$

0.40

Adjustments:(b)

Gain on sale of businesses

(4,545)

(0.03)

(3,652)

(0.03)

Adjusted net income attributable to common shares

$

34,946

$

0.27

$

47,655

$

0.37

(a)

Net income attributable to common shares and earnings per common share are calculated based on the diluted weighted average common shares outstanding, as presented in table II.

(b)

Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding.

The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit. For the three months ended March 31, 2019 and 2020, the adjustments to net income attributable to common shares include estimated income tax expense of approximately $1.8 million and $3.4 million, respectively.

Cision View original content:http://www.prnewswire.com/news-releases/select-medical-holdings-corporation-announces-results-for-its-first-quarter-ended-march-31-2020-301050503.html

SOURCE Select Medical Holdings Corporation

Categories

PRNewswire Press Releases

Next Articles